MRTX-1133

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameMRTX-1133
Drug Alias NameMRTX-1133
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMirati Therapeutics IncArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMirati Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A